Cargando…

Effects of Guanxinshutong Capsules as Complementary Treatment in Patients With Chronic Heart Failure: Study Protocol for a Randomized Controlled Trial

Chronic heart failure (CHF) is a common cardiovascular disease with high mortality and a poor prognosis, which places heavy burdens upon society and families. Traditional Chinese medicine (TCM) has been used extensively as complementary treatment for CHF. Guanxinshutong (GXST) capsules are used comm...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yu, Xu, Jiaping, Yang, Jiehong, Zhang, Ling, Pan, Yuanjiang, Dou, Liping, Zhou, Peng, Xu, Yizhou, Li, Chang, He, Yu, Zhou, Huifen, Yu, Li, Chen, Jingwen, Huang, Shuwei, Fu, Wei, Wan, Haitong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7840487/
https://www.ncbi.nlm.nih.gov/pubmed/33519434
http://dx.doi.org/10.3389/fphar.2020.571106
_version_ 1783643584201752576
author Wang, Yu
Xu, Jiaping
Yang, Jiehong
Zhang, Ling
Pan, Yuanjiang
Dou, Liping
Zhou, Peng
Xu, Yizhou
Li, Chang
He, Yu
Zhou, Huifen
Yu, Li
Chen, Jingwen
Huang, Shuwei
Fu, Wei
Wan, Haitong
author_facet Wang, Yu
Xu, Jiaping
Yang, Jiehong
Zhang, Ling
Pan, Yuanjiang
Dou, Liping
Zhou, Peng
Xu, Yizhou
Li, Chang
He, Yu
Zhou, Huifen
Yu, Li
Chen, Jingwen
Huang, Shuwei
Fu, Wei
Wan, Haitong
author_sort Wang, Yu
collection PubMed
description Chronic heart failure (CHF) is a common cardiovascular disease with high mortality and a poor prognosis, which places heavy burdens upon society and families. Traditional Chinese medicine (TCM) has been used extensively as complementary treatment for CHF. Guanxinshutong (GXST) capsules are used commonly for the treatment of coronary heart disease (CHD). Experimental research and small-sample clinical trials have shown that GXST can attenuate CHF. However, the effects of GXST as complementary medicine in CHF treatment lack high-quality clinical evidence. We have designed a multicenter, randomized, double-blind, placebo-controlled clinical trial that explores the efficacy and safety of using GXST compared with placebo for patients with CHF with reduced left ventricular ejection fraction (LVEF). A total of 480 participants will be assigned randomly to the GXST group or placebo group at a 2:1 ratio. GXST and placebo will be added to standard treatment for 12 weeks, and then followed up for another 40 weeks. The primary outcome is the improvement value of 6-min walk distance, and the secondary outcomes include plasma levels of N-terminal pro-B-type natriuretic peptide, New York Heart Association classification, Minnesota Living with Heart Failure Questionnaire scores, echocardiographic parameters, and clinical endpoint events. Adverse events will be monitored throughout the trial. Data will be analyzed following a predefined statistical analysis plan. This study will show the effects of the specific use of GXST in CHF patients with reduced LVEF. The Research Ethics Committee of the Second Affiliated Hospital of Zhejiang Chinese Medical University has approved this study (2019-Y-003-02). Written informed consent of patients will be required. This trial is registered in the Chinese Clinical Trial Registry (ChiCTR1900023877). Our results will be disseminated to the public through peer-reviewed journals, academic conferences, and the Internet.
format Online
Article
Text
id pubmed-7840487
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-78404872021-01-29 Effects of Guanxinshutong Capsules as Complementary Treatment in Patients With Chronic Heart Failure: Study Protocol for a Randomized Controlled Trial Wang, Yu Xu, Jiaping Yang, Jiehong Zhang, Ling Pan, Yuanjiang Dou, Liping Zhou, Peng Xu, Yizhou Li, Chang He, Yu Zhou, Huifen Yu, Li Chen, Jingwen Huang, Shuwei Fu, Wei Wan, Haitong Front Pharmacol Pharmacology Chronic heart failure (CHF) is a common cardiovascular disease with high mortality and a poor prognosis, which places heavy burdens upon society and families. Traditional Chinese medicine (TCM) has been used extensively as complementary treatment for CHF. Guanxinshutong (GXST) capsules are used commonly for the treatment of coronary heart disease (CHD). Experimental research and small-sample clinical trials have shown that GXST can attenuate CHF. However, the effects of GXST as complementary medicine in CHF treatment lack high-quality clinical evidence. We have designed a multicenter, randomized, double-blind, placebo-controlled clinical trial that explores the efficacy and safety of using GXST compared with placebo for patients with CHF with reduced left ventricular ejection fraction (LVEF). A total of 480 participants will be assigned randomly to the GXST group or placebo group at a 2:1 ratio. GXST and placebo will be added to standard treatment for 12 weeks, and then followed up for another 40 weeks. The primary outcome is the improvement value of 6-min walk distance, and the secondary outcomes include plasma levels of N-terminal pro-B-type natriuretic peptide, New York Heart Association classification, Minnesota Living with Heart Failure Questionnaire scores, echocardiographic parameters, and clinical endpoint events. Adverse events will be monitored throughout the trial. Data will be analyzed following a predefined statistical analysis plan. This study will show the effects of the specific use of GXST in CHF patients with reduced LVEF. The Research Ethics Committee of the Second Affiliated Hospital of Zhejiang Chinese Medical University has approved this study (2019-Y-003-02). Written informed consent of patients will be required. This trial is registered in the Chinese Clinical Trial Registry (ChiCTR1900023877). Our results will be disseminated to the public through peer-reviewed journals, academic conferences, and the Internet. Frontiers Media S.A. 2021-01-14 /pmc/articles/PMC7840487/ /pubmed/33519434 http://dx.doi.org/10.3389/fphar.2020.571106 Text en Copyright © 2021 Wang, Xu, Yang, Zhang, Pan, Dou, Zhou, Xu, Li, He, Zhou, Yu, Chen, Huang, Fu and Wan. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Wang, Yu
Xu, Jiaping
Yang, Jiehong
Zhang, Ling
Pan, Yuanjiang
Dou, Liping
Zhou, Peng
Xu, Yizhou
Li, Chang
He, Yu
Zhou, Huifen
Yu, Li
Chen, Jingwen
Huang, Shuwei
Fu, Wei
Wan, Haitong
Effects of Guanxinshutong Capsules as Complementary Treatment in Patients With Chronic Heart Failure: Study Protocol for a Randomized Controlled Trial
title Effects of Guanxinshutong Capsules as Complementary Treatment in Patients With Chronic Heart Failure: Study Protocol for a Randomized Controlled Trial
title_full Effects of Guanxinshutong Capsules as Complementary Treatment in Patients With Chronic Heart Failure: Study Protocol for a Randomized Controlled Trial
title_fullStr Effects of Guanxinshutong Capsules as Complementary Treatment in Patients With Chronic Heart Failure: Study Protocol for a Randomized Controlled Trial
title_full_unstemmed Effects of Guanxinshutong Capsules as Complementary Treatment in Patients With Chronic Heart Failure: Study Protocol for a Randomized Controlled Trial
title_short Effects of Guanxinshutong Capsules as Complementary Treatment in Patients With Chronic Heart Failure: Study Protocol for a Randomized Controlled Trial
title_sort effects of guanxinshutong capsules as complementary treatment in patients with chronic heart failure: study protocol for a randomized controlled trial
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7840487/
https://www.ncbi.nlm.nih.gov/pubmed/33519434
http://dx.doi.org/10.3389/fphar.2020.571106
work_keys_str_mv AT wangyu effectsofguanxinshutongcapsulesascomplementarytreatmentinpatientswithchronicheartfailurestudyprotocolforarandomizedcontrolledtrial
AT xujiaping effectsofguanxinshutongcapsulesascomplementarytreatmentinpatientswithchronicheartfailurestudyprotocolforarandomizedcontrolledtrial
AT yangjiehong effectsofguanxinshutongcapsulesascomplementarytreatmentinpatientswithchronicheartfailurestudyprotocolforarandomizedcontrolledtrial
AT zhangling effectsofguanxinshutongcapsulesascomplementarytreatmentinpatientswithchronicheartfailurestudyprotocolforarandomizedcontrolledtrial
AT panyuanjiang effectsofguanxinshutongcapsulesascomplementarytreatmentinpatientswithchronicheartfailurestudyprotocolforarandomizedcontrolledtrial
AT douliping effectsofguanxinshutongcapsulesascomplementarytreatmentinpatientswithchronicheartfailurestudyprotocolforarandomizedcontrolledtrial
AT zhoupeng effectsofguanxinshutongcapsulesascomplementarytreatmentinpatientswithchronicheartfailurestudyprotocolforarandomizedcontrolledtrial
AT xuyizhou effectsofguanxinshutongcapsulesascomplementarytreatmentinpatientswithchronicheartfailurestudyprotocolforarandomizedcontrolledtrial
AT lichang effectsofguanxinshutongcapsulesascomplementarytreatmentinpatientswithchronicheartfailurestudyprotocolforarandomizedcontrolledtrial
AT heyu effectsofguanxinshutongcapsulesascomplementarytreatmentinpatientswithchronicheartfailurestudyprotocolforarandomizedcontrolledtrial
AT zhouhuifen effectsofguanxinshutongcapsulesascomplementarytreatmentinpatientswithchronicheartfailurestudyprotocolforarandomizedcontrolledtrial
AT yuli effectsofguanxinshutongcapsulesascomplementarytreatmentinpatientswithchronicheartfailurestudyprotocolforarandomizedcontrolledtrial
AT chenjingwen effectsofguanxinshutongcapsulesascomplementarytreatmentinpatientswithchronicheartfailurestudyprotocolforarandomizedcontrolledtrial
AT huangshuwei effectsofguanxinshutongcapsulesascomplementarytreatmentinpatientswithchronicheartfailurestudyprotocolforarandomizedcontrolledtrial
AT fuwei effectsofguanxinshutongcapsulesascomplementarytreatmentinpatientswithchronicheartfailurestudyprotocolforarandomizedcontrolledtrial
AT wanhaitong effectsofguanxinshutongcapsulesascomplementarytreatmentinpatientswithchronicheartfailurestudyprotocolforarandomizedcontrolledtrial